Three2001
2 hours ago
Waited all weekend, thinking we were going to start the week off nicely. Waited the whole day, expecting buying at eod. Instead, we get some fking bozo placing a market sell and fking the whole day up. Give us that news NOW. Make this moron regret this sale today. Very disheartening. I know, I know, approval by Sunday. If not during the week, I don't even want to think what other morons might show up.
$RDGL
familyof5
2 days ago
The power of a BDD
Credit: chereb19
NEWS --December 20, 2023 Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation (BDD)
https://www.otcmarkets.com/stock/RDGL/news/Radiogel-Precision-Radionuclide-Therapy-Receives-FDA-Breakthrough-Device-Designation?id=425373
chereb19 Re: None
Thursday, February 22, 2024 10:59:59 AM
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=173899170
The power of a BDD
Firstly, the BDD fast-tracks RadioGel's journey to market. The FDA prioritizes review for these devices, meaning closer interactions, quicker feedback, and potentially a significantly reduced path to market. This is crucial for RadioGel, as it promises a minimally invasive and potentially curative treatment for difficult-to-reach or radiation-resistant tumors.
Beyond speed, the BDD grants RadioGel access to dedicated FDA experts. This fosters open communication, clearer expectations, and streamlined development. Imagine navigating the regulatory process with a roadmap in hand – that's what the BDD offers. This collaborative approach minimizes uncertainties and saves precious resources, propelling RadioGel closer to patients who need it most.
The BDD also acts as a powerful magnet for investors and payers. It's a stamp of approval, highlighting RadioGel's potential to revolutionize cancer treatment. This can facilitate funding and open doors to earlier reimbursement discussions, ensuring wider patient access to this potentially life-saving technology.
Finally, the BDD distinguishes RadioGel in the crowded medical device landscape. It proclaims it as cutting-edge, innovative, and potentially transformative. This market differentiation is invaluable, giving RadioGel a crucial edge in attracting investment, collaborators, and, most importantly, patients who stand to benefit from its unique approach.
In conclusion, RadioGel's BDD is not just a recognition of its potential; it's a powerful engine propelling it towards making a real difference in the lives of cancer patients. The faster development, closer collaboration, and enhanced visibility it brings pave the way for a future where RadioGel's minimally invasive, targeted therapy becomes a beacon of hope for those battling some of the toughest cancers.
Remember, this is just the beginning of RadioGel's journey. With the BDD wind in its sails, it's poised to make waves in the cancer treatment landscape, offering new hope and potentially brighter tomorrows for patients worldwide.
https://www.otcmarkets.com/stock/RDGL/news/Radiogel-Precision-Radionuclide-Therapy-Receives-FDA-Breakthrough-Device-Designation?id=425373
NEWS -- Radiogel™ Precision Radionuclide Therapy™ Receives FDA Breakthrough Device Designation
Richland WA, Dec. 20, 2023 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL), Vivos Inc is pleased to announce that the Food and Drug Administration has granted RadioGel Precision Radionuclide Therapy the designation as a Breakthrough Device pursuant to the FDA’s Breakthrough Devices Program.
Dr. Mike Korenko stated “We are pleased with the FDA’s decision to grant Breakthrough Device Designation following our recent data submissions. The FDA did a very thorough review. The analysis in our Risk Management Report concluded that RadioGel™ is intrinsically safe and our animal therapy data verified its effectiveness. We are currently working closely with Mayo Clinic for our initial indication for use of Radiogel for delivering “therapeutic radiation to solid metastatic tumors in lymph nodes associated with papillary thyroid cancer, accessible by percutaneous direct needle injection, in patients who are not surgical candidates or have declined surgery, had non-radioiodine avid disease and had limited burden regional nodal disease.” The Breakthrough Device classification will enhance the schedule priority for our upcoming IDE submission seeking authorization to begin human clinical trials.
The FDA’s Breakthrough Devices program facilitates accelerated development and expedites the review of breakthrough technologies to help patients potentially gain timely access to technologies that can provide more effective treatment options.
Contact for journalists:
Mike Korenko
Email: mailto://MKorenko@RadioGel.com
familyof5
2 days ago
Understanding the IDE Submission Process and FDA Review Timeline
This IDE filing addressed 63 FDA comments from previous correspondences, including reports on two complex studies: RadioGel® genotoxicity and the retention of RadioGel® at the injection site in VX2 tumors in rabbits.
The Investigational Device Exemption (IDE) submission is a crucial step in gaining FDA approval to conduct human clinical trials for new medical devices. When a company submits an IDE application, it includes detailed reports, studies, and data demonstrating the device’s safety and efficacy. Once the application is submitted, https://radiogel.com/ide-submission the FDA has a 30-day review period to evaluate the information provided. During this time, the FDA can respond with one of three possible outcomes
Approval: Full authorization to proceed with the clinical trials.
Approval with Conditions: Authorization to proceed with specific conditions or modifications required.
Disapproval: Denial of the application, requiring further data or changes.
kayak_wench
2 days ago
New journal article published July 1 citing Vivo's rabbit test from 2019.
https://link.springer.com/article/10.1186/s12951-024-02547-9
This is a fabulous paper summarizing use of hydrogels in the treatment of liver cancer in the Journal of Nanobiotechnology. This journal has an Impact Factor of 10.2!!, very high. A high impact factor translators to more readers and more acceptance by the medical community. The rating is called 'impact' factor for a reason.
An impact factor of 10 can be considered excellent – although unreachable in many categories – as in 2020 only 3.65% of the journals had an impact factor of 10 or higher.
The paper has a section on radiotherapy that describes 3 hydrogels that have radioactive particles. Its going to be hard for the medical community to ignore radiogel when such highly read/revered journal's keep describing it as safe and effective.
Here is section on radiogel from the paper.
90Y (Yttrium-90) is a radionuclide that can achieve localized, continuous, low-dose radiation by emitting ß-rays without causing significant radiation damage to surrounding normal tissue cells [117]. The treatment can achieve precise therapeutic effects against tumors, especially for the treatment of primary liver cancer, colorectal cancer liver metastases, and other liver tumors [118]. Fisher created an injectable hydrogel called 90Y-RadioGelTM that contained insoluble, microscopic yttrium-phosphate particles carried by a sterile solution [119]. After the polymer solution was injected into a rabbit with a VX2 liver tumor, the solution solidified at a temperature close to body temperature (30–37 °C). Therefore, the therapeutic agent containing 90Y could lodge at the tumor site and deliver localized, precise ß radiation. Liquid scintillation counting and microCT showed that the radiation from 90Y was contained in the tumor and tumor margins. Therefore, neighboring normal organs or tissues receive a modest dose of radiation dosage, or even a negligible dose. In conclusion, 90Y-RadioGel™ is a radiologically safe and effective therapy option for solid tumors.
mikepgator
2 days ago
The wording seems more like the FDA will let you know what the official date is. Kind of like if you send something to a court it is not official until the clerk stamps it.
Upon receipt of an IDE application, sponsors are notified via email of the date that FDA received the original application and the IDE number assigned. An IDE application is considered approved 30 days after it has been received by the FDA, unless the FDA otherwise informs the sponsor via email prior to 30 calendar days from the date of receipt, that the IDE is approved, approved with conditions, or disapproved.